vs
Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and Walker & Dunlop, Inc. (WD). Click either name above to swap in a different company.
EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $340.0M, roughly 1.8× Walker & Dunlop, Inc.). EXELIXIS, INC. runs the higher net margin — 40.8% vs -12.9%, a 53.8% gap on every dollar of revenue. On growth, EXELIXIS, INC. posted the faster year-over-year revenue change (5.6% vs -0.4%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $-680.1M). Over the past eight quarters, Walker & Dunlop, Inc.'s revenue compounded faster (22.1% CAGR vs 18.7%).
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Walker & Dunlop, Inc. is one of the largest commercial real estate finance and advisory services firms in the United States and internationally.
EXEL vs WD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $598.7M | $340.0M |
| Net Profit | $244.5M | $-13.9M |
| Gross Margin | 95.6% | — |
| Operating Margin | 39.3% | -17.2% |
| Net Margin | 40.8% | -12.9% |
| Revenue YoY | 5.6% | -0.4% |
| Net Profit YoY | 74.8% | -131.0% |
| EPS (diluted) | $0.89 | $-0.41 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $598.7M | — | ||
| Q4 25 | $597.8M | $340.0M | ||
| Q3 25 | $568.3M | $337.7M | ||
| Q2 25 | $555.4M | $319.2M | ||
| Q1 25 | $566.8M | $237.4M | ||
| Q4 24 | — | $341.5M | ||
| Q3 24 | $539.5M | $292.3M | ||
| Q2 24 | $637.2M | $270.7M |
| Q1 26 | $244.5M | — | ||
| Q4 25 | $193.6M | $-13.9M | ||
| Q3 25 | $184.8M | $33.5M | ||
| Q2 25 | $159.6M | $34.0M | ||
| Q1 25 | $139.9M | $2.8M | ||
| Q4 24 | — | $44.8M | ||
| Q3 24 | $118.0M | $28.8M | ||
| Q2 24 | $226.1M | $22.7M |
| Q1 26 | 95.6% | — | ||
| Q4 25 | 96.9% | — | ||
| Q3 25 | 96.6% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.5% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 96.8% | — | ||
| Q2 24 | 97.2% | — |
| Q1 26 | 39.3% | — | ||
| Q4 25 | 39.6% | -17.2% | ||
| Q3 25 | 37.6% | 13.6% | ||
| Q2 25 | 33.6% | 14.5% | ||
| Q1 25 | 28.8% | 2.2% | ||
| Q4 24 | — | 15.3% | ||
| Q3 24 | 25.2% | 12.8% | ||
| Q2 24 | 43.3% | 10.4% |
| Q1 26 | 40.8% | — | ||
| Q4 25 | 32.4% | -12.9% | ||
| Q3 25 | 32.5% | 9.9% | ||
| Q2 25 | 28.7% | 10.6% | ||
| Q1 25 | 24.7% | 1.2% | ||
| Q4 24 | — | 13.1% | ||
| Q3 24 | 21.9% | 9.9% | ||
| Q2 24 | 35.5% | 8.4% |
| Q1 26 | $0.89 | — | ||
| Q4 25 | $0.69 | $-0.41 | ||
| Q3 25 | $0.65 | $0.98 | ||
| Q2 25 | $0.55 | $0.99 | ||
| Q1 25 | $0.47 | $0.08 | ||
| Q4 24 | — | $1.32 | ||
| Q3 24 | $0.40 | $0.85 | ||
| Q2 24 | $0.77 | $0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.1B | $299.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.2B | $1.7B |
| Total Assets | $2.8B | $5.1B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $1.1B | — | ||
| Q4 25 | $988.5M | $299.3M | ||
| Q3 25 | $791.1M | $274.8M | ||
| Q2 25 | $1.0B | $233.7M | ||
| Q1 25 | $1.1B | $181.0M | ||
| Q4 24 | — | $279.3M | ||
| Q3 24 | $1.2B | $179.8M | ||
| Q2 24 | $1.0B | $208.1M |
| Q1 26 | $2.2B | — | ||
| Q4 25 | $2.2B | $1.7B | ||
| Q3 25 | $2.0B | $1.8B | ||
| Q2 25 | $2.1B | $1.8B | ||
| Q1 25 | $2.2B | $1.7B | ||
| Q4 24 | — | $1.7B | ||
| Q3 24 | $2.3B | $1.7B | ||
| Q2 24 | $2.1B | $1.7B |
| Q1 26 | $2.8B | — | ||
| Q4 25 | $2.8B | $5.1B | ||
| Q3 25 | $2.7B | $5.8B | ||
| Q2 25 | $2.8B | $4.7B | ||
| Q1 25 | $2.9B | $4.5B | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | $3.0B | $4.6B | ||
| Q2 24 | $2.8B | $4.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $333.5M | $-664.3M |
| Free Cash FlowOCF − Capex | $332.4M | $-680.1M |
| FCF MarginFCF / Revenue | 55.5% | -200.0% |
| Capex IntensityCapex / Revenue | 0.2% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.36× | — |
| TTM Free Cash FlowTrailing 4 quarters | $875.8M | $-2.2B |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $333.5M | — | ||
| Q4 25 | $290.3M | $-664.3M | ||
| Q3 25 | $49.0M | $-948.1M | ||
| Q2 25 | $211.4M | $-238.5M | ||
| Q1 25 | $240.3M | $-281.1M | ||
| Q4 24 | — | $129.4M | ||
| Q3 24 | $271.3M | $-202.0M | ||
| Q2 24 | $119.5M | $-237.8M |
| Q1 26 | $332.4M | — | ||
| Q4 25 | $288.8M | $-680.1M | ||
| Q3 25 | $46.2M | $-950.4M | ||
| Q2 25 | $208.5M | $-241.0M | ||
| Q1 25 | $236.3M | $-284.7M | ||
| Q4 24 | — | $116.4M | ||
| Q3 24 | $263.1M | $-204.0M | ||
| Q2 24 | $113.0M | $-241.7M |
| Q1 26 | 55.5% | — | ||
| Q4 25 | 48.3% | -200.0% | ||
| Q3 25 | 8.1% | -281.5% | ||
| Q2 25 | 37.5% | -75.5% | ||
| Q1 25 | 41.7% | -120.0% | ||
| Q4 24 | — | 34.1% | ||
| Q3 24 | 48.8% | -69.8% | ||
| Q2 24 | 17.7% | -89.3% |
| Q1 26 | 0.2% | — | ||
| Q4 25 | 0.2% | 4.6% | ||
| Q3 25 | 0.5% | 0.7% | ||
| Q2 25 | 0.5% | 0.8% | ||
| Q1 25 | 0.7% | 1.5% | ||
| Q4 24 | — | 3.8% | ||
| Q3 24 | 1.5% | 0.7% | ||
| Q2 24 | 1.0% | 1.4% |
| Q1 26 | 1.36× | — | ||
| Q4 25 | 1.50× | — | ||
| Q3 25 | 0.27× | -28.34× | ||
| Q2 25 | 1.32× | -7.02× | ||
| Q1 25 | 1.72× | -102.07× | ||
| Q4 24 | — | 2.89× | ||
| Q3 24 | 2.30× | -7.01× | ||
| Q2 24 | 0.53× | -10.49× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EXEL
| Cabometyx | $544.7M | 91% |
| Collaboration | $52.1M | 9% |
| Collaborative Arrangementwith Takeda | $5.9M | 1% |
| Cometriq | $1.8M | 0% |
WD
Segment breakdown not available.
